NCT05526924View on ClinicalTrials.gov

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 7, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck CarcinomaHead and Neck Cancer Stage IVHead and Neck Cancers - Throat
Interventions
RADIATION

Chemoradiation

A combination of chemotherapy and radiation given at the same time to treat cancer.

DRUG

Pamiparib

An anti-cancer drug that targets specific cells to help fight cancer given by IV (through a needle inserted into a vein).

DRUG

Hydroxyurea

A chemotherapy drug given in pill form; used to treat leukemia and head and neck cancer.

DRUG

Fluorouracil (5FU)

A chemotherapy drug used to treat different types of cancer.

DRUG

Tislelizumab

An anti-cancer drug.

Trial Locations (1)

60637

RECRUITING

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER